AGCO Agriculture Foundation to Donate BRL 240,000 to Amigos do Bem institution
The AGCO Agriculture Foundation (the “Foundation”), a private foundation with the vision to prevent and relieve hunger through sustainable agriculture development, will donate BRL 240,000 ($50,000) to Amigos do Bem. The resources will support the “Cashew Project: Transformation Seedlings”, which aims to develop small cashew farmers in the northeast of Brazil, generating work and income and positively impacting extremely vulnerable families.
The donation from the Foundation will be used to purchase and distribute 30,000 fruit tree seedlings, fertilizers and farming kits, as well as provide training, technical support and continuous monitoring of small farmers in the northeast of Brazil. The initiative will support 100 families, reaching more than 500 people directly and indirectly, in addition to supporting the neutralization of 500 tons of CO2 per year with the planting of cashew trees.
“The cashew seedling initiative directly and positively impacts small producers and the environment. Most importantly, it builds a pathway into a guaranteed market for their crops," said Roger Batkin, Chair of the Foundation. “This type of social impact initiative is strongly aligned with the Foundation’s approach for impactful programs that support food security and sustainable agricultural development in rural communities.”
The cashew seedlings to be distributed to farmers will be planted on their own land, with a guaranteed purchase of products at market value, encouraging the role of Brazilian nut suppliers and generating direct and indirect income opportunities.
“By supporting the initiative, we will contribute to transforming the lives of small farmers and their families in the northeastern hinterland, strengthening local agricultural development in a sustainable way and promoting the autonomy and empowerment of these communities,” emphasizes Rodrigo Junqueira, Vice President Massey Ferguson and General Manager South America.
Created in 1993, the nonprofit institution Amigos do Bem promotes continuous education, job and income generation projects and access to water, housing, and health. The social project regularly aids 150,000 people throughout the northeast region of Brazil, with a focus on eradicating extreme poverty. "The Cashew Project started in 2018, with the distribution of surplus seedlings from our own plantations so that small-scale producers could find a source of income and subsistence. It ended up revolutionizing the cashew nut chain in the region," comments André de Luca, Executive Director at Amigos do Bem.
For the next five years, Amigos do Bem project goal is to neutralize 2,300 tons of carbon by planting 150,000 cashew trees, in addition to reaching around 420 farmers, generating income for their families.
About AGCO
AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $12.7 billion in 2022. For more information, visit www.AGCOcorp.com. For company news, information, and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
About AGCO Agriculture Foundation
Founded by AGCO Corporation (NYSE: AGCO) in 2018, the AGCO Agriculture Foundation is a private foundation with the vision to prevent and relieve hunger. The Foundation promotes impact programs that support food security, sustainable agricultural development and build the necessary agricultural infrastructure in marginalized farming communities. The Foundation is domiciled in Vaduz, Liechtenstein and its operations are managed from Duluth, Georgia, USA. For more information, visit https://www.agcofoundation.org/.
About the NGO Amigos do Bem
For 30 years, the Amigos do Bem institution has been working to transform lives in the northeastern hinterland, the poorest and most isolated region in Brazil. Every month, 150,000 people, who live in 300 villages in extreme poverty, are assisted with ongoing projects in education, work and income, water, housing, and health. We promote social inclusion and local development, meeting 12 of the 17 UN Sustainable Development Goals. We created a Sustainable Social Development Model and several initiatives with a positive impact with the participation of almost 11,000 volunteers. For more information, visit https://www.amigosdobem.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230803234399/en/
Contact information
Aryn Drawdy, Corporate Communications Director
Aryn.Drawdy@agcocorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
